Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in HFrEF with Severe Renal Insufficiency
NCT05737186Phase 4Terminated
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in heart failure with reduced ejection fraction (HFrEF), sponsored by Peking University People's Hospital. Started Mar 2023; status: terminated.
02
Drugs
dapagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT05737186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05737186.